Sort   by:  
 Page size 
MetabolomicsTargeting PI3K inhibitor resistance in breast cancer with metabolic drugs

Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2-) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves ...

2026-08-21 | MTBLS11671 | MetaboLights
ProteomicsPI3Kinase Isoforms in Pancreatic cancer
Pancreatic ductal adenocarcinoma is one of the most lethal cancers, with a 5 year-survival rate below 5%. Lack of curative treatment and failure of targeted therapies urge the need to identify novel efficient therapeutic strategy. Achievement of this goal will be obtained through the identification ...
ORGANISM(S): Homo sapiens (Human) 
2022-02-28 | PXD008410 | Pride
Pi3k signaling pathway isoforms 
TranscriptomicsTargeting the Phosphoinositide 3-Kinase p110-alpha Isoform Impairs Cell Proliferation, Survival and Tumor Growth in Small Cell Lung Cancer
Purpose: The phosphoinositide 3-kinase (PI3K) pathway is fundamental for cell proliferation and survival and is frequently altered and activated in neoplasia, including carcinomas of the lung. In this study we investigated the potential of targeting the catalytic class IA PI3K isoforms in small cell...
ORGANISM(S): Homo sapiens 
2012-12-01 | E-GEOD-40564 | biostudies-arrayexpress
TranscriptomicsPhosphatidylinositol 3-Kinase (PI3K) Signaling via Glycogen Synthase Kinase-3 (Gsk-3) Regulates DNA Methylation of Imprinted Loci.
The two vertebrate Gsk-3 isoforms, Gsk-3a and Gsk-3b, are encoded by distinct genetic loci and exhibit mostly redundant function in murine embryonic stem cells (ESCs). Here we report that deletion of both Gsk-3a and Gsk-3b in mouse ESCs results in misregulated expression of imprinted genes and hypom...
ORGANISM(S): Mus musculus 
2010-11-15 | E-GEOD-20015 | biostudies-arrayexpress
TranscriptomicsAKT Isoform Specificity Downstream of PIK3CA Mutation Impacts Estradiol and PI3K Inhibitor Response in Breast Cancer Cells
Background: PIK3CA mutations are observed in >30% of breast cancers, which are more common in estrogen receptor (ERα)-positive breast cancer compared with ERα-negative breast cancer. AKT1, 2, and 3 isoforms, major isoforms downstream of PI3K, modulate ERα activity. It is unknown whether PIK3CA mu...
ORGANISM(S): Homo sapiens 
2016-08-10 | E-GEOD-60759 | biostudies-arrayexpress
TranscriptomicsTumor gene expression analysis - PI3K Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Of the 142 patients enrolled in Study CHRONOS-1, an open-label, single-arm, Phase II study evaluating the efficacy and safety of single-agent copanlisib in patients with relapsed or refractory, indolent B-cell lymphoma (NCT01660451; Part B), 96 archival formalin-fixed paraffin-embedded tumor tissues...
ORGANISM(S): Homo sapiens 
2017-12-01 | E-MTAB-6088 | biostudies-arrayexpress
TranscriptomicsRNAseq of tumor samples from CT26 syngeneic mouse treated with a PI3Ka/d inhibitor (AZD8835)
PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also regulates the immune system and inhibition of PI3Kdelta modulate the tumor immune microenvironment of pre-clinical mo...
ORGANISM(S): Mus musculus 
2019-01-08 | E-MTAB-7386 | biostudies-arrayexpress
UnknownExpression of variant isoforms of the tyrosine kinase SYK differentially regulates cervical cancer progression through PI3K/AKT pathway.
Not available
S-EPMC11585633 | biostudies-literature
UnknownIsoforms S and L of MRPL33 from alternative splicing have isoform‑specific roles in the chemoresponse to epirubicin in gastric cancer cells via the PI3K/AKT signaling pathway.
Not available
S-EPMC6438423 | biostudies-literature
TranscriptomicsGene expression profiles of Herceptin-resistant breast cancer cells
Herceptin (trastuzumab) is a humanized monoclonal antibody targeted to the Her2 receptor tyrosine kinase. Despite a robust response rate to Herceptin-based therapies in Her2-positive patients, resistance frequently arises within one year of the initial response. To address the mechanism of Hercept...
ORGANISM(S): Homo sapiens 
2009-08-21 | E-GEOD-15043 | biostudies-arrayexpress
Sort   by:  
 Page size